NexgenRx Inc.
NXG.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.52M | 3.50M | 3.05M | 2.93M | 3.04M |
| Total Other Revenue | 77.70K | -334.50K | 300.50K | 214.70K | 77.20K |
| Total Revenue | 3.59M | 3.17M | 3.35M | 3.14M | 3.12M |
| Cost of Revenue | 535.60K | 373.40K | 556.00K | 567.70K | 594.40K |
| Gross Profit | 3.06M | 2.80M | 2.80M | 2.57M | 2.53M |
| SG&A Expenses | 1.99M | 2.07M | 2.13M | 2.10M | 1.92M |
| Depreciation & Amortization | 167.10K | 194.90K | 227.50K | 233.40K | 218.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.70M | 2.64M | 2.91M | 2.90M | 2.74M |
| Operating Income | 898.00K | 527.20K | 442.20K | 245.00K | 383.10K |
| Income Before Tax | 866.80K | 382.80K | 411.60K | 239.00K | 351.40K |
| Income Tax Expenses | -16.40K | 512.40K | -16.60K | -16.50K | -15.90K |
| Earnings from Continuing Operations | 883.30K | -129.70K | 428.20K | 255.50K | 367.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 883.30K | -129.70K | 428.20K | 255.50K | 367.30K |
| EBIT | 898.00K | 527.20K | 442.20K | 245.00K | 383.10K |
| EBITDA | 937.30K | 566.70K | 669.70K | 478.40K | 602.00K |
| EPS Basic | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 71.12M | 71.12M | 71.12M | 71.12M | 71.12M |
| Average Diluted Shares Outstanding | 77.05M | 71.12M | 84.25M | 76.92M | 76.72M |
| Dividend Per Share | -- | 0.00 | 0.00 | 0.00 | -- |
| Payout Ratio | 2.69% | -269.72% | 65.89% | 109.92% | 6.26% |